|
Alzheimers: FDA approval of dementia drug based on biomarkers?
MedPage Today Are biomarker-based endpoints adequate to prove efficacy in Alzheimer's drug trials? We asked two prominent experts: Eric Reiman, MD, executive director of the Banner Alzheimer's Institute in Phoenix, and Mary Sano, PhD, professor of psychiatry at the … |
